Bengaluru: Biocon Limited has announced that its Canadian subsidiary has received Health Canada's Notice of Compliance (NOC) ...
Biocon receives Health Canada approval for its Yesintek (ustekinumab) autoinjector for plaque psoriasis & other autoimmune ...
Biocon's Yesintek autoinjector approved by Health Canada for multiple conditions, expanding treatment options and ...
Biocon wins Health Canada approval for Yesintek autoinjector, expanding autoimmune biosimilar options in Canada. Read more.
Embecta closed its acquisition of Owen Mumford Holdings on Friday, shifting its focus from diabetes products to broader medical supplies. Embecta, which announced the deal in March, agreed to pay 100 ...
Hello, and welcome back to the Bank of America Healthcare Conference. I'm Tazeen Ahmad. I'm one of the biotech analysts here at the bank. Our next presenting company is argenx. Sitting up here on ...
AstraZeneca’s SAPHNELO® (anifrolumab-fnia) has been approved in the US for self-administration as a once-weekly autoinjector, the SAPHNELO Pen, for the treatment of adult patients with systemic lupus ...
Anifrolumab-fnia, an IFNAR1-blocking monoclonal antibody, is now authorized for weekly subcutaneous self-administration in adult SLE alongside corticosteroids, antimalarials, and/or immunosuppressants ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results